Cellnovo Limited (ENXTPA:CLNV) acquired commercial license for Artificial Pancreas technology from TypeZero Technologies LLC on April 18, 2017. TypeZero’s Artificial Pancreas (AP) software, known as inControl AP, will be incorporated directly into Cellnovo’s Bluetooth-enabled micropump. Tristan Roquet Montégon of NewCap and Chris Gardner, Chris Welsh and Laura Thornton of Consilium Strategic Communications acted as public relation advisors for Cellnovo. Cellnovo Limited (ENXTPA:CLNV) completed the acquisition of commercial license for Artificial Pancreas technology from TypeZero Technologies LLC on April 18, 2017.